Why new Alzheimer’s drugs are dividing regulators worldwide

New Alzheimer’s drugs are raising hopes, but modest benefits, ARIA safety risks, high costs, and regulatory disagreements show how uncertain the path to meaningful treatment remains.

From hope to uncertainty: regulating novel drugs for Alzheimer's disease. Image Credit: ER Pictures / Shutterstock

A recent World Report published in The Lancet examines the evolving therapeutic landscape and regulatory hurdles surrounding Alzheimer’s disease (AD). Regulators debate whether the clinical benefits of new drugs outweigh their safety concerns and whether those benefits can translate into meaningful patient outcomes. This has led to conflicting approval decisions across countries. Scientists are now developing safer drugs that target broader disease mechanisms and testing them in people at high risk for AD before symptoms appear. Such efforts could advance precision medicine and help reduce the global burden of AD.

AD is a brain disease that damages nerve cells and causes millions of dementia cases worldwide. The disease burden is projected to rise from 55 million dementia cases globally in 2020 to 78 million by 2030, increasing the need for better treatments. Although many new drugs are being tested, health agencies often differ in their views on approving new drugs based on clinical outcomes. Agencies such as the United States Food and Drug Administration (US FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) often differ from the European Medicines Agency (EMA).